← Leaderboards
Pavan Reddy
University Of Michigan At Ann Arbor
$35,237,005
Attributed
$38,518,618
Total exposure
24
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$63,388,897 · 25
FDA$985,432 · 1
By mechanism
P01$20,475,839 · 7
R01$19,896,123 · 10
P30$15,833,277 · 4
T32$4,648,137 · 2
R44$2,004,306 · 1
UG1$1,048,791 · 1
Top collaborators
- Gregory Yanik7 shared
- Jordan A Shavit5 shared
- Martin Devenport3 shared
- Yang Liu2 shared
- Muneesh Tewari2 shared
- Steven M. Devine1 shared
- Daisuke Nakada1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- E Neil Marsh$6,332,365
- David Eric Sandberg$9,835,385
- Eric C Martens$9,107,472
- Robert M Strieter$9,675,893
- Gabriel Nunez$34,455,724
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicMolecularCellsResponseComplicationBiologyRegulationInsightBone Marrow TransplantationT-LymphocytePlayMalignant - DescriptorAllogeneic Bone Marrow TransplantationMediatingSeveritiesModalityImmuneClinical TrialsLeadGraft-Vs-Host DiseasePathway InteractionsHematopoietic Stem Cell TransplantationAcute Graft Versus Host DiseaseTissues
Grant awards (118)
Baylor College of Medicine Cancer Center - Cancer Center Support Grant$3,768,411
P30 · FY2025 · CA · contact PI
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD$636,920
R01 · FY2025 · AI · contact PI
Leadership, Planning and Evaluation$583,878
P30 · FY2025 · CA · contact PI
Development$380,959
P30 · FY2025 · CA · contact PI
Project 1: Mitochondrial Bioenergetics and Metabolism of ISCS in GVHD$309,580
P01 · FY2025 · CA · contact PI
Administrative Core$148,399
P30 · FY2025 · CA · contact PI
Baylor College of Medicine Cancer Center-Cancer Center Support Grant$3,517,288
P30 · FY2024 · CA · contact PI
Host and Microbial Metabolism in Graft versus Host Disease$2,092,435
P01 · FY2024 · HL
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD$643,890
R01 · FY2024 · AI · contact PI
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD$312,530
P01 · FY2024 · HL · contact PI
Project 1: Mitochondrial Bioenergetics and Metabolism of ISCS in GVHD$294,101
P01 · FY2024 · CA · contact PI
The role of HIV Vif in clonal hematopoiesis and malignant transformation (HIV-Associated Cancers in Aging Populations)$250,000
P30 · FY2024 · CA · contact PI
Administrative and Biostatistics Core$95,122
P01 · FY2024 · HL · contact PI
Baylor College of Medicine Cancer Center-Cancer Center Support Grant$3,517,288
P30 · FY2023 · CA · contact PI
Host and Microbial Metabolism in Graft versus Host Disease$2,190,546
P01 · FY2023 · HL
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD$635,782
R01 · FY2023 · AI · contact PI
COPII dependent regulation of T cell alloimmunity$621,640
R01 · FY2023 · HL · contact PI
Boxer Training Program in Molecular and Translational Hematology$344,999
T32 · FY2023 · HL
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD$327,290
P01 · FY2023 · HL · contact PI
Project 1: Mitochondrial Bioenergetics and Metabolism of ISCS in GVHD$309,580
P01 · FY2023 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$145,866
UG1 · FY2023 · HL
Administrative and Biostatistics Core$99,934
P01 · FY2023 · HL · contact PI
Baylor College of Medicine Cancer Center-Cancer Center Support Grant$3,517,288
P30 · FY2022 · CA · contact PI
Host and Microbial Metabolism in Graft versus Host Disease$2,242,449
P01 · FY2022 · HL · contact PI
Intestinal tissue intrinsic mechanisms in regulation of GI GVHD$627,781
R01 · FY2022 · AI · contact PI
COPII dependent regulation of T cell alloimmunity$585,730
R01 · FY2022 · HL · contact PI
Boxer Training Program in Molecular and Translational Hematology$377,980
T32 · FY2022 · HL
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD$334,976
P01 · FY2022 · HL · contact PI
Targeting Novel DAMP mediated signaling pathways to mitigate GVHD$271,887
R01 · FY2022 · CA · contact PI
Enhancing Sexual Orientation and Gender Identity Data Collection across the Duncan Cancer Center$149,766
P30 · FY2022 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$146,105
UG1 · FY2022 · HL
Administrative and Biostatistics Core$103,114
P01 · FY2022 · HL · contact PI
Targeting novel DAMP mediated signaling pathways to mitigate GVHD$1
R01 · FY2022 · CA · contact PI
Host and Microbial Metabolism in Graft versus Host Disease$2,295,629
P01 · FY2021 · HL · contact PI
COPII dependent regulation of T cell alloimmunity$585,730
R01 · FY2021 · HL · contact PI
Boxer Training Program in Molecular and Translational Hematology$463,605
T32 · FY2021 · HL
Targeting novel DAMP mediated signaling pathways to mitigate GVHD$379,528
R01 · FY2021 · CA · contact PI
Oncology Research Training Grant$363,968
T32 · FY2021 · CA · contact PI
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD$343,106
P01 · FY2021 · HL · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$145,952
UG1 · FY2021 · HL
Administrative and Biostatistics Core$106,084
P01 · FY2021 · HL · contact PI
Host and Microbial Metabolism in Graft versus Host Disease$2,314,611
P01 · FY2020 · HL · contact PI
COPII dependent regulation of T cell alloimmunity$585,730
R01 · FY2020 · HL · contact PI
Boxer Training Program in Molecular and Translational Hematology$512,521
T32 · FY2020 · HL
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$485,432
R01 · FY2020 · FD
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity$477,565
R01 · FY2020 · CA · contact PI
Oncology Research Training Grant$378,724
T32 · FY2020 · CA · contact PI
Crosstalk between host (IEC) mitochondria and microbial metabolism in GVHD$351,000
P01 · FY2020 · HL · contact PI
Project 1: HDAC inhibition and GVHD$327,440
P01 · FY2020 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$147,352
UG1 · FY2020 · HL
Administrative and Biostatistics Core$109,200
P01 · FY2020 · HL · contact PI
Boxer Training Program in Molecular and Translational Hematology$486,433
T32 · FY2019 · HL
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity$463,239
R01 · FY2019 · CA · contact PI
Development of novel strategy for treatment of steroid refractory GVHD$440,356
R01 · FY2019 · HL · contact PI
Targeting novel DAMP mediated signaling pathways to mitigate GVHD$416,353
R01 · FY2019 · CA · contact PI
Oncology Research Training Grant$362,594
T32 · FY2019 · CA · contact PI
Project 1: HDAC inhibition and GVHD$317,617
P01 · FY2019 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$149,355
UG1 · FY2019 · HL
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$982,509
R44 · FY2018 · CA
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$500,000
R01 · FY2018 · FD
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity$477,565
R01 · FY2018 · CA · contact PI
Development of novel strategy for treatment of steroid refractory GVHD$440,356
R01 · FY2018 · HL · contact PI
Targeting novel DAMP mediated signaling pathways to mitigate GVHD$429,228
R01 · FY2018 · CA · contact PI
Oncology Research Training Grant$336,089
T32 · FY2018 · CA · contact PI
Project 1: HDAC inhibition and GVHD$335,457
P01 · FY2018 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$144,028
UG1 · FY2018 · HL
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$4,319
R44 · FY2018 · CA
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$1,017,478
R44 · FY2017 · CA
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity$477,565
R01 · FY2017 · CA · contact PI
Targeting novel DAMP mediated signaling pathways to mitigate GVHD$426,640
R01 · FY2017 · CA · contact PI
Development of novel strategy for treatment of steroid refractory GVHD$426,268
R01 · FY2017 · HL · contact PI
Oncology Research Training Grant$335,634
T32 · FY2017 · CA · contact PI
Role of noncoding RNA in Regulating GVHD$322,663
R01 · FY2017 · CA · contact PI
Project 1: HDAC inhibition and GVHD$298,786
P01 · FY2017 · CA · contact PI
University of Michigan Core Clinical Center for the BMT Research Network$170,133
UG1 · FY2017 · HL
Cellular and molecular mechanisms of target tissue resistance for mitigating GVHD severity$477,565
R01 · FY2016 · CA · contact PI
Development of novel strategy for treatment of steroid refractory GVHD$426,268
R01 · FY2016 · HL · contact PI
Targeting antigen presentation to enhance GVL responses after Bone Marrow Transpl$388,750
R01 · FY2016 · HL · contact PI
Oncology Research Training Grant$343,097
T32 · FY2016 · CA · contact PI
Role of noncoding RNA in Regulating GVHD$322,663
R01 · FY2016 · CA · contact PI
Project 1: HDAC inhibition and GVHD$316,161
P01 · FY2016 · CA · contact PI
Development of novel strategy for treatment of steroid refractory GVHD$389,620
R01 · FY2015 · HL · contact PI
Targeting antigen presentation to enhance GVL responses after Bone Marrow Transpl$382,918
R01 · FY2015 · HL · contact PI
Oncology Research Training Grant$342,493
T32 · FY2015 · CA · contact PI
Role of noncoding RNA in Regulating GVHD$322,663
R01 · FY2015 · CA · contact PI
HDAC Inhibition to prevent GVHD$705,818
P01 · FY2014 · CA · contact PI
Targeting antigen presentation to enhance GVL responses after Bone Marrow Transpl$380,975
R01 · FY2014 · HL · contact PI
Role of noncoding RNA in Regulating GVHD$312,983
R01 · FY2014 · CA · contact PI
Experimental BMT$248,583
P01 · FY2014 · CA · contact PI
Development of a Novel Strategy to Prevent Experimental GVHD$144,816
R01 · FY2014 · CA · contact PI
Targeting antigen presentation to enhance GVL responses after Bone Marrow Transpl$370,090
R01 · FY2013 · HL · contact PI
Role of noncoding RNA in Regulating GVHD$322,663
R01 · FY2013 · CA · contact PI
Experimental BMT$309,596
P01 · FY2013 · CA · contact PI
HDAC Inhibition to prevent GVHD$288,197
P01 · FY2013 · CA · contact PI
Development of a Novel Strategy to Prevent Experimental GVHD$140,535
R01 · FY2013 · CA · contact PI
HDAC Inhibition to prevent GVHD$773,323
P01 · FY2012 · CA · contact PI
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses$371,626
R01 · FY2012 · HL · contact PI
Role of APCs in Modulating Donor Natural Tregs Mediated Suppression of GVHD$364,230
R01 · FY2012 · AI · contact PI
Experimental BMT$233,641
P01 · FY2012 · CA · contact PI
Development of a Novel Strategy to Prevent Experimental GVHD$149,709
R01 · FY2012 · CA · contact PI
HDAC Inhibition to prevent GVHD$776,379
P01 · FY2011 · CA · contact PI
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses$371,870
R01 · FY2011 · HL · contact PI
Role of APCs in Modulating Donor Natural Tregs Mediated Suppression of GVHD$364,469
R01 · FY2011 · AI · contact PI
Experimental BMT$234,066
P01 · FY2011 · CA · contact PI
Development of a Novel Strategy to Prevent Experimental GVHD$149,759
R01 · FY2011 · CA · contact PI
HDAC Inhibition to prevent GVHD$838,093
P01 · FY2010 · CA · contact PI
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses$372,106
R01 · FY2010 · HL · contact PI
Role of APCs in Modulating Donor Natural Tregs Mediated Suppression of GVHD$368,385
R01 · FY2010 · AI · contact PI
Experimental BMT$241,395
P01 · FY2010 · CA · contact PI
Development of a Novel Strategy to Prevent Experimental GVHD$153,821
R01 · FY2010 · CA · contact PI
Role of APCs in Modulating Donor Natural Tregs Mediated Suppression of GVHD$372,336
R01 · FY2009 · AI · contact PI
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses$372,336
R01 · FY2009 · HL · contact PI
Role of APCs in Modulating Donor Natural Tregs Mediated Suppression of GVHD$372,559
R01 · FY2008 · AI · contact PI
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses$372,559
R01 · FY2008 · HL · contact PI
Mechanisms of IL-18 Mediated Regulation of GVHD and GVL$122,364
K08 · FY2006 · AI · contact PI
Mechanisms of IL-18 Mediated Regulation of GVHD and GVL$122,364
K08 · FY2005 · AI
Mechanisms of IL-18 Mediated Regulation of GVHD and GVL$111,564
K08 · FY2004 · AI
Mechanisms of IL-18 Mediated Regulation of GVHD and GVL$111,564
K08 · FY2003 · AI